Category: Costing
-
New Niger study paper makes the investment case for integrated REACH azithromycin
A new paper from the REACH AVENIR study team in Niger provides a detailed micro-costing of mass drug administration (MDA) with azithromycin, demonstrating the excellent value for money represented by REACH interventions. The study also provides ample evidence of the value of locally-led implementation research in informing policy and practice. The paper, “Micro-costing for national-scale…
-
Integration, ownership, and responsibility: A REACH Network reflection
by Professor Samba O Sow, Co-chair of the REACH Network and Director General of the Center for Vaccine Development – Mali At our recent Annual Meeting in Abu Dhabi, integration emerged as one of the most discussed and, perhaps, most misunderstood themes. In a time of tightening global health budgets, humanitarian strain, and growing expectations…
-
REACH Network publishes Annual Meeting report, survey results
—
published by
The REACH Network is proud to publish its 2025 Annual Meeting report. The REACH Network’s Annual Meeting for 2025 was held in Abu Dhabi, United Arab Emirates. This year again, it proved to be a key date in the Network’s calendar, drawing participation from all six member countries, along with key technical partners and donors.…
-
